ArticleJournal of biomedical research2018

Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis.

Fei Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.